Veterinary Renal Diseases Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.77 Billion |
| Market Size (2029) | USD 2.55 Billion |
| CAGR (2024 - 2029) | 7.53 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Veterinary Renal Diseases Market Analysis
The Veterinary Renal Diseases Market size is estimated at USD 1.7 billion in 2024, and is expected to reach USD 2.5 billion by 2029, growing at a CAGR of 7.53% during the forecast period (2024-2029).
The veterinary renal diseases market is driven by the increasing incidences of renal diseases in animals, the widespread use of pet food as a treatment for renal diseases, the prevalence of kidney stones and cystitis in animals, and campaigns to raise awareness of diseases. The market is expected to grow due to an increase in diagnoses driven by the expanded use of imaging and blood work procedures. Veterinarians utilize blood tests and urine analysis (urinalysis) to assess animal kidney function by measuring the amounts of waste products and other substances that normally get filtered or managed by healthy kidneys. Further examinations, such as radiography (X-rays), abdominal ultrasounds, and, in certain cases, microscopic analysis of biopsy samples, may aid in the assessment of an animal that may have renal issues.
The surge in the incidences of chronic kidney diseases among cats and dogs is also expected to boost the growth of the market in the coming years. According to information released by the MSD Veterinary Manual in October 2022, chronic kidney diseases are usually incurable and commonly progress, and these diseases frequently take months or years for symptoms to manifest. It is more prevalent in animals between the ages of five and six. Chronic kidney disease (CKD) is a prevalent condition in pets, affecting up to 10% of dogs and 35% of cats globally. This high incidence underscores the need for effective diagnostic and treatment strategies. The prevalence of small animals in the general population is less than 1% or 3%.
Moreover, the COVID-19 demographic and rising disposable incomes have also driven more of the population to adopt pets, thus boosting the market’s growth. Globally, dogs and cats are the most common domestic pets. Hence, the number of pets in a country is usually measured by these animals. According to World Population Review 2024, the United States undoubtedly leads the world in pet ownership, with approximately 70 million domestic dogs and 74 million domestic cats.
Another characteristic of the market is the practice of collaborating with competitors to strengthen one's position and increase sales. For instance, in March 2023, Boehringer Ingelheim formed a strategic partnership with New Ruipeng Group, a leading veterinary service provider in China. This collaboration focuses on expanding Boehringer Ingelheim's presence in the East Asian veterinary market and leveraging advanced diagnostic and treatment solutions for renal diseases in pets. Another significant development came in July 2022 when Dechra Pharmaceuticals PLC acquired Piedmont Animal Health LLC for USD 210 million. This strategic acquisition aimed to bolster Dechra's product development resources, particularly in the veterinary renal diseases market.
The veterinary renal diseases market is poised for significant growth, fueled by advancements in diagnostics and treatments and increasing awareness among pet owners. Continued innovation and early detection are key to improving outcomes and quality of life for affected animals.
However, the market faces restraints due to the high cost of advanced diagnostic and treatment options, limiting accessibility for some pet owners. Additionally, the lack of awareness and education about the early detection and management of renal diseases in pets further hampers market growth.
Veterinary Renal Diseases Market Trends
The Feline Segment is Expected to Hold a Dominant Market Share During the Forecast Period
Cats tend to have a higher prevalence of renal disorders due to a number of variables, such as their unique anatomy, breed vulnerability, and a higher incidence of ailments, including chronic kidney diseases. Age-related renal degeneration is prevalent in cats, and kidney issues may run in some breeds' families. In addition, cats may conceal their symptoms, which could postpone diagnosis. Among the animal types, cats have the largest percentage of veterinary renal disorders due to the combined effects of all these factors. According to the American Veterinary Medical Association (AVMA) data from 2021, cats with CKD had a disease-specific incidence range of 2% to 20%.
Government sources such as the National Institutes of Health (NIH) highlighted the advancements in veterinary medicine that improved the management of CKD in cats. Innovations in diagnostic technologies, such as blood and urine tests for early markers of kidney disease, have enhanced veterinarians' ability to detect CKD at earlier stages. Additionally, the development of specialized diets and medications designed to slow the progression of CKD has been instrumental in improving outcomes for affected cats.
Furthermore, the USDA's Animal and Plant Health Inspection Service (APHIS) in 2022 noted that the economic impact of feline renal disease is substantial, with pet owners in the United States spending an estimated USD 2 billion annually on veterinary care and treatments for CKD. This includes costs related to diagnostic tests, medications, therapeutic diets, and regular monitoring. As the pet population ages and the number of diagnosed cases of CKD rises, the demand for effective management strategies in the feline segment of the veterinary renal diseases market is expected to continue growing.
Hence, due to the abovementioned factors, the feline segment is expected to witness significant growth in the upcoming years.
Asia-Pacific is Anticipated Register a Significant CAGR During the Forecast Period
Asia-Pacific is projected to experience substantial growth in the veterinary renal diseases market. Pet owners in this area are becoming increasingly aware of the importance of maintaining their pets' overall health. East Asia, in particular, is driving technological advancements in animal health. The rising awareness of animal health and the growing pet ownership in countries like China and Japan have created an ideal environment for leading healthcare companies to expand their operations.
In recent years, India, China, and other Asia-Pacific countries have seen a rise in pet ownership, reflecting a strong interest in adopting pets. The impact of the COVID-19 pandemic on people's mental health, coupled with the shift to work-from-home arrangements, has led many individuals to seek the psychological support and companionship that pets provide. As a result, dog adoptions in countries have increased significantly. In China, pet ownership has also seen a substantial increase, particularly in urban areas. According to World Population Review 2024, as of 2023, there were around 58.1 million pet dogs and 66.5 million pet cats in the country. In addition, according to a Euromonitor International report, the pet dog population in Singapore was around 114,000 in 2023, up by almost 3% from 2019. The pet cat population hovered around 94,000 this year, a jump of almost 10% compared with 2019.
Additionally, advancements in precision management systems are enhancing animal welfare. For instance, real-time automatic video monitoring in chicken houses can identify areas of low or abnormal occupancy and detect malfunctioning feed, triggering automatic alerts for the owner. In addition, the rising adoption of artificial intelligence in drug discovery and diagnostic platforms is also transforming the market. For instance, in October 2023, Zoetis announced the launch of Vetscan Imagyst, an AI-powered diagnostic platform, in the Asia-Pacific market. This platform includes an application for AI-based urine sediment analysis, which helps in quick and accurate diagnosis of renal conditions in pets.
Therefore, owing to the factors mentioned above, the veterinary renal diseases market is anticipated to expand in Asia-Pacific during the forecast period.
Veterinary Renal Diseases Industry Overview
The veterinary renal diseases market is fragmented due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold significant market shares and are well known. The key players in the market include Mars Inc., Nestle Purina PetCare, Hill's Pet Nutrition Inc., The JM Smucker Company, Dechra Veterinary Products Limited, Merck & Co. Inc., Elanco, Vetpharma, IDEXX, Carestream Health, and FUJIFILM Holdings Corporation.
Veterinary Renal Diseases Market Leaders
-
Hill's Pet Nutrition, Inc.
-
Elanco
-
Vetpharma
-
Merck & Co., Inc.,
-
Carestream Health
*Disclaimer: Major Players sorted in no particular order
Veterinary Renal Diseases Market News
- January 2024: Zoetis Inc. announced the expansion of its multi-application diagnostics platform, Vetscan Imagyst, to include AI Urine Sediment analysis. This new feature allows for precise, in-clinic sediment analysis of fresh urine, enabling clinicians to make swift treatment decisions.
- September 2023: Elanco Animal Health Incorporated announced that the initial shipments of Varenzin-CA1 (molidustat oral suspension) are being sent to veterinary clinics nationwide. This treatment, conditionally approved by the US Food and Drug Administration (FDA), is the first and only option for managing non-regenerative anemia in cats with chronic kidney disease (CKD).
- June 2023: IDEXX Laboratories Inc. introduced the first veterinary diagnostic test to detect kidney injury in cats and dogs. The new IDEXX Cystatin B Test will be part of renal health panels, offering valuable clinical insights for approximately two million yearly patient visits. This test was expected to be available at IDEXX Reference Laboratories in the United States and Canada later this year, with plans to expand to Europe in 2024.
Veterinary Renal Diseases Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Renal Complications in Animal
4.2.2 Rising Demand for Renoprotective Diets
4.2.3 Surge in Pet Ownership
4.3 Market Restraints
4.3.1 Off-Label Use of Drugs in Veterinary Treatment
4.3.2 Lack of Early Diagnosis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type
5.1.1 Diagnosis
5.1.1.1 Test Kits and Consumables
5.1.1.2 Instruments
5.1.2 Treatment
5.1.2.1 Drugs
5.1.2.2 Therapeutic Food Supplements
5.1.2.3 Ringer Lactate Solution
5.2 By Animal Type
5.2.1 Canine
5.2.2 Feline
5.2.3 Bovine
5.2.4 Equine
5.2.5 Other Animal Types
5.3 By Indication
5.3.1 Renal Failure
5.3.2 Chronic Kidney Disease
5.3.3 Renal Cystitis
5.3.4 Kidney Stones
5.3.5 Other Indications
5.4 By Distribution Channel
5.4.1 Veterinary Hospitals and Clinics
5.4.2 Pet Specialty Stores
5.4.3 E-commerce
5.4.4 Other Distribution Channels
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Mars Inc.
6.1.2 Nestle Purina PetCare
6.1.3 Hill's Pet Nutrition Inc.
6.1.4 The JM Smucker Company
6.1.5 Dechra Veterinary Products Limited
6.1.6 Merck & Co. Inc.
6.1.7 Elanco
6.1.8 Vetpharma
6.1.9 IDEXX
6.1.10 Carestream Health
6.1.11 FUJIFILM Holdings Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Veterinary Renal Diseases Industry Segmentation
Veterinary renal diseases, including chronic kidney disease (CKD) and acute kidney injury, are significant health concerns for pets, especially cats and dogs. These conditions can lead to severe health issues and reduced quality of life if not managed properly. Advancements in diagnostics and treatments are improving early detection and management of diseases, enhancing outcomes for affected animals.
The veterinary renal diseases market is segmented by type (diagnosis (test kits and consumables and instruments) and treatment (drugs, therapeutic food supplements, and ringer lactate solution)), animal type (canine, feline, bovine, equine, and other animal types), indication (renal failure, chronic kidney disease, renal cystitis, kidney stones, and other indications), distribution channel (veterinary hospitals and clinics, pet specialty stores, e-commerce, and other distribution channels), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market sizes and forecasts in terms of value (USD) for the above segments.
Veterinary Renal Diseases Market Research FAQs
How big is the Veterinary Renal Diseases Market?
The Veterinary Renal Diseases Market size is expected to reach USD 1.77 billion in 2024 and grow at a CAGR of 7.53% to reach USD 2.55 billion by 2029.
What is the current Veterinary Renal Diseases Market size?
In 2024, the Veterinary Renal Diseases Market size is expected to reach USD 1.77 billion.
Who are the key players in Veterinary Renal Diseases Market?
Hill's Pet Nutrition, Inc., Elanco, Vetpharma, Merck & Co., Inc., and Carestream Health are the major companies operating in the Veterinary Renal Diseases Market.
Which is the fastest growing region in Veterinary Renal Diseases Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Veterinary Renal Diseases Market?
In 2024, the North America accounts for the largest market share in Veterinary Renal Diseases Market.
What years does this Veterinary Renal Diseases Market cover, and what was the market size in 2023?
In 2023, the Veterinary Renal Diseases Market size was estimated at USD 1.64 billion. The report covers the Veterinary Renal Diseases Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Veterinary Renal Diseases Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Veterinary Renal Diseases Industry Report
Statistics for the 2024 Veterinary Renal Diseases market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Veterinary Renal Diseases analysis includes a market forecast outlook for 2024 to (2024to2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
